摘要
目的探讨孟鲁斯特辅治小儿哮喘的疗效和预防喘息反复发作的作用。方法将确诊为小儿哮喘的106例病人随机分为治疗组52例和对照组54例,两组均给予常规吸入皮质激素治疗,哮喘发作时临时吸入沙丁胺醇对症治疗;治疗组加用孟鲁斯特口服,1~3岁3mg,每天1次,3~13岁5mg,每天1次,共3~12个月,进行为期1~2年的跟踪随访。结果治疗组总有效率明显高于对照组(P<0.05);治疗组咳嗽喘息及肺部体征消失时间均短于对照组(P<0.05);治疗组日后喘息复发次数明显低于对照组(P<0.05)。结论孟鲁斯特辅治小儿哮喘疗效显著,未见不良反应。
Objective To study the curative effect of Montelukast on infantile asthma and evaluate the efficiency of montelukast in decreasing the incidence of infantile asthma. Methods 106 cases of infantile asthma were categorized in two groups, 52 cases in therapy group and 54 cases in control group, two groups were treated with budesonide. During the observation, imbibing ;2 was further given as asthma spasm! Montelukast was applied in therapy group, 3mg, and qn for 1-3years old, 5mg and qn for 3-13years old. Period of treatment was 3-12months. The time of follow up was 1-2 years. Results The cure rate of therapy group is significant higher than control group (P〈0.05), the difference has statistical difference. Incidence of asthma with montelukast is less than without montelukast. Conclusion Montelukast can conspicuous increase the therapy effects of infantile asthma, Montelukast is an effective way to decrease the incidence of infantile asthma, and it is without adverse reactions.
出处
《西部医学》
2013年第5期713-714,共2页
Medical Journal of West China
关键词
孟鲁斯特
小儿哮喘
治疗
预防
Montelukast
infantile asthma
Treatment
Precaution